HOME     CONTACT     BACK

 
 
 
THE PHARMA REVIEW (MAY 2010)

Romidepsin: A Histone Deacetylase Inhibitor for the Treatment of Cutaneous T Cell Lymohoma

Seema Jain, Nidhi B. Agarwal

Abstract
Romidepsin (depsipeptide, FK228) is a new anticancer drug approved for the treatment of cutaneous T cell lymphoma (CTCL). It is a bicyclic peptide isolated from Chromobacterium violaceum bacteria. It acts by inhibiting histone deacetylase enzymes which regulate transcription process and other cellular processes in the cells. It is indicated in dose of 14 mg/m, infused intravenously over a 4-hour period on day 1, day 8 and day 15 of a 28-day cycle of treatment in those patients who have received at least one prior systemic therapy for CTCL. In clinical trials the most commonly reported adverse effects with the use of romidepsin are gastrointestinal disorders like nausea, vomiting, diarrhea, loss of appetite and tiredness. This drug is currently in various phase of clinical trials for the treatment of other malignancies like multiple myeloma, head and neck cancer and lung cancer etc., which might indicate its potential use in these malignancies in future.

 

For full text of this article contact the publisher on info@kppub.com

 

Go to Content Index Page

PHARMA REVIEW - ARTICLES ARCHIVE ( COMPLETE LIST)

The above content is an abstract only. For the full Article please contact:
KONGPOSH Publications Pvt. Ltd.
ICS House, C-19, Commercial Complex, SDA, Opp. IIT Gate, New Delhi, India -110016
Tel.: 26855839, 20057149, Fax: 91-11-26855876
Email: info@kppub.com / fpc@vsnl.com, Website: http://www.kppub.com

 
 
 

 Copyright 2008. KONGPOSH PUBLICATIONS Pvt. Ltd.